ecosystem / people / chris-ing
C

Chris Ing

Co-founder & Chief Science Officer, ProteinQure

BiotechToronto

Chris Ing is a co-founder and the chief science officer of ProteinQure, the Toronto biotech that designs protein-based drugs with molecular simulation and machine learning. ProteinQure's team page says he holds an MSc in physics from the University of Waterloo and a PhD in biochemistry from the University of Toronto. BetaKit's 2019 seed coverage listed him as chief strategy officer.

Chris hasn’t spoken on a TechTO, TechVancouver or TechWaterloo stage. This profile is here because Chris co-founded ProteinQure, which appears in 1 talk in the archive.

Around the web ×1

Quick answers

Did Chris Ing co-found ProteinQure?

Yes. ProteinQure's team page, checked September 23, 2026, lists "Chris Ing" under its Founders group with the title "Chief Science Officer (CSO) - Co-Founder". BetaKit reported on July 29, 2019 that "ProteinQure was founded in 2017 by Siow, CTO Tomas Babej, chief strategy officer Chris Ing, and Mark Fingerhuth, head of R&D."

What is his role at ProteinQure today?

Chief science officer. ProteinQure's team page, checked September 23, 2026, gives his title as "Chief Science Officer (CSO) - Co-Founder". When BetaKit covered the company's seed round on July 29, 2019, it described him as chief strategy officer.

What is his scientific background?

Physics and biochemistry. ProteinQure's team page, checked September 23, 2026, says: "Chris has an MSc in Physics from University of Waterloo, and a PhD in Biochemistry from the University of Toronto. He has used physical simulations to study chemical and biological systems from one to one million atoms." His personal site, cing.github.io, checked the same day, describes him as a "Computational biophysicist & co-founder at ProteinQure".

How did ProteinQure start?

Through Creative Destruction Lab. A Creative Destruction Lab blog post dated December 9, 2025 says ProteinQure joined the program in 2017 through its quantum stream, and that its founding team included "Tomas Babej, Mark Fingerhuth, Christopher Ing and Lucas Siow". The same post says the company's AI-designed peptide PQ203 was then in Phase I trials for advanced metastatic cancer.

Suggest an edit
This is you? Claim this profileAsk to be removed
Know someone who belongs here? Suggest a profile
Maintained by TechTO · facts sourced and dated · last reviewed Sep 23, 2026